Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q1 2022 · 10-Q
Revenue$964.32K$964.32Kno prior Q1 2021 on file Net Income-$9.91M-$9.91MN/M vs Q1 2021 EPS Diluted-$1.19-$1.19N/M vs Q1 2021 Operating Income-$9,794,745N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1015.7%
Net margin-1027.7%
ended Mar 31, 2022 · filed May 13, 2022 · 43 d after period end